TRIM21 and interstitial lung disease: Patients with ILD were more likely to have Ro-52 antibodies (64.04%) and most antisynthetase antibodies (e.g. Jo-1, PL-7, PL-12, and EJ antibodies), while patients without ILD were more likely to have TIF1γ and SRP antibodies (10.89%, 9.90%, respectively).